Decrease of asymmetric dimethyl arginine after anti-TNF therapy in patients with rheumatoid arthritis

Area of Science:

• Cardiovascular Medicine
• Rheumatology
• Pharmacology

Background:

• Chronic inflammatory diseases like rheumatoid arthritis (RA) are linked to higher rates of atherosclerosis and cardiovascular events.
• Asymmetric dimethyl arginine (ADMA) impairs endothelial function, an early stage of atherosclerosis, by inhibiting nitric oxide synthase.
• Tumor necrosis factor (TNF) can inhibit ADMA's enzymatic degradation, suggesting anti-TNF therapies might normalize ADMA levels.

Purpose of the Study:

• To investigate the impact of TNF inhibitors on serum ADMA levels in patients with RA.
• To explore the potential of anti-TNF therapy in managing cardiovascular risk factors associated with RA.

Main Methods:

• The study assessed serum ADMA levels in patients undergoing treatment with TNF inhibitors for RA.
• Observational study design to evaluate the effect of anti-TNF agents on ADMA concentrations.

Main Results:

• Preliminary findings suggest that anti-TNF drugs may influence serum ADMA levels in RA patients.
• A potential correlation between TNF inhibition and ADMA level modulation was observed.

Conclusions:

• Anti-TNF agents might play a role in regulating ADMA levels in rheumatoid arthritis.
• Longer-term studies are required to validate the role of ADMA in cardiovascular risk assessment for RA patients treated with anti-TNF therapy.